DDX18P5

Across TCGA pan-cancer cohorts, DDX18P5 RNA is linked to patient survival in 15 of 34 cancer types, making it the most broadly survival-associated DDX18P5 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher DDX18P5 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated DDX18P5 expression acts as an unfavorable survival marker, although some lineages such as BLCA and LUAD show a favorable association.

LIHC, BLCA, and LUAD are the cancer types where DDX18P5 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Tertile	All	0.299	0.469	<.001	64	view →
BLCA	DFS	Median	III,IV	0.441	0.208	<.001	35	view →
LUAD	DFS	Tertile	IV	0.787	0.240	.011	20	view →
OV	DFS	Tertile	IV	0.307	0.619	.003	18	view →
UCS	OS	Tertile	III,IV	0.305	0.618	.049	12	view →
MESO	DFS	Quartile	III,IV	0.125	0.394	<.001	12	view →
UVM	DFS	Tertile	III,IV	0.079	0.635	.021	9	view →
KIRP	OS	Tertile	II,III,IV	0.468	0.840	.021	8	view →
BRCA	DFS	Tertile	All	0.965	0.939	.021	7	view →
LGG	OS	Tertile	All	0.844	0.909	.008	7	view →
GBM	DFS	Quartile	All	0.465	0.180	.004	6	view →
CESC	OS	Median	IV	0.101	0.498	.033	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 15 lineages.

DDX18P5–LIHC (DFS)

Open the LIHC breakdown →